In my new in-depth report, I am reporting a whole range of little-known facts about Russia’s no. 1 public company. If you thought you knew Gazprom, you’ll have to think again!
I anticipated a higher-than-expected, soon-to-be-launched bid for Belmond Ltd, the luxury hotel operator. LVMH just made a $2.6bn offer for the company!
Is now the time to invest your money into Argentina and does the country have a chance to become the top-choice of investors in 2019?
Sotheby’s shareholders seem to have a sixth sense for an impending crisis. With its share price currently falling, you better keep it on your watch list.
The Orient Express is up for sale. Could there still be a quick profit to be made, even with the proposed takeover price already being public?
Is there any such thing as making money without taking undue risks? Find out in this acecdote from the German stock market.
With a $400 trillion pension funding shortfall looming, what should you brace yourself for – and how can you escape as much as possible?
How did Argentinean farmland holding CRESUD manage to produce zero return for investors despite spiraling farmland values?
What went wrong, and why the lessons learned matter to anyone who has ever considered subscribing to an IPO placement of a reputable company.
A growing income stream and prospective dividend payments make the Eurotunnel share an interesting bet to safely stash money away.
A case-study of General Electric and how to buy at the top and be forever stuck in a downwards spiral. Will the same hold true for the FAANGs?
The US had spectacular bank blow-ups, and led the world into the biggest banking crisis of living memory. Still, it has major advantages over Europe.
Valuations of some British stocks are ridiculously low. This could be a generational investment opportunity for small-cap sleuths.
I had mobilised GBP 30m to buy a portfolio of real estate in Sark, with plans to IPO the company. How did it go, and what may happen next?
Guyana could become the world’s richest country. Besides oil and gas stocks, it also entails an unknown, century-old land company.
This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.
If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.
This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.
